Home
Issues
2022
May 2022 - Vol 15 No 3
March 2022 - Vol 15 No 2
January 2022 - Vol 15 No 1 – Online Only
2021
November 2021 - Vol 14 No 7
October 2021 - Vol 14 No 6 | Biosimilars
September 2021 - Vol 14 No 5
July 2021 - Vol 14 No 4
May 2021 - Vol 14 No 3
March 2021 - Vol 14 No 2
January 2021 - Vol 14 No 1
2020
November 2020, Vol 13, No 6
September 2020 - Vol 13 no 5
July 2020 - Vol 13 no 4
May 2020 - Vol 13 no 3
March 2020 - Vol 13 no 2
January 2020 - Vol 13 No 1
2019
November 2019 - Vol 12 No 4
August 2019 - Vol 12 No 3
May 2019 - Vol 12 No 2
February 2019 - Vol 12 No 1
Issue Archive
Special Issues
Supplements
ASK THE EXPERT: First-Line Treatment of Metastatic Non-small cell Lung Cancer
Part 1
Guide to New FDA Approvals
2019 Fourth Annual Guide
2018 Third Annual Guide
2017 Second Annual Guide
2016 First Annual Guide
Categories
Conference Correspondent
ASCO 2021 Wrap-Up - Breast Cancer
Web Exclusives
Ovarian Cancer Overview
Interview with the Innovators
All Web Exclusives
Drug Updates
FDA Approvals, News & Updates
In the News
Press Releases
Online First
Media Library
Videos
Audiocasts
Quick Quiz
CE
About
About TOP
Advertise
Editorial Board
Contact Us
Resources
Submit
Author Guidelines
Christin Melton
Authored Items
A Review of Investigational Drugs at HOPA
Christin Melton
TOP - MAY 2011, VOL 4, NO 3
in
Conference Correspondent
Review of New Oncology Drugs at HOPA
Christin Melton
TOP - March/April 2011, VOL 4, NO 2
in
Conference Correspondent
Cost-Containment Strategies
Christin Melton
TOP - March/April 2011, VOL 4, NO 2
in
Conference Correspondent
Making Cancer Drugs Worth the Cost
Christin Melton
TOP - March/April 2011, VOL 4, NO 2
Are You Talking to Patients About Smoking Cessation?
Christin Melton
TOP - March/April 2011, VOL 4, NO 2
in
Conference Correspondent
Drug Shortages: A Growing Crisis in Oncology
Christin Melton
TOP - March/April 2011, VOL 4, NO 2
in
Drug Updates
FDA Panel Recommends Stricter Process for Accelerated Approval of Cancer Drugs
Christin Melton
TOP - March/April 2011, VOL 4, NO 2
in
In the News
Ipilimumab (Yervoy) Is First Melanoma Drug Approved in a Decade
Christin Melton
TOP - March/April 2011, VOL 4, NO 2
in
Skin Cancer
Considerations for Cancer Treatment–Induced Diarrhea
Christin Melton
TOP - March/April 2011, VOL 4, NO 2
in
Supportive Care
Managing Elderly Patients Who Have Comorbidities
Christin Melton
TOP - March/April 2011, VOL 4, NO 2
in
Supportive Care
Medicare Plans to Cover Provenge
Christin Melton
TOP - March/April 2011, VOL 4, NO 2
in
Genitourinary Cancers
Variation in Prescribing Instructions Confuses Patients on Multidrug Regimens
Christin Melton
TOP - March/April 2011, VOL 4, NO 2
in
Practical Issues for Pharmacists
ASCO Calls for EGFR Mutation Testing in Some Patients with Lung Cancer
Christin Melton
TOP - Daily
Considerations for Cancer-treatment–Induced Diarrhea
Christin Melton
TOP - Daily
Medicare Says Agency Plans to Cover Provenge
Christin Melton
TOP - Daily
Ipilimumab (Yervoy) Becomes First Melanoma Drug Approved in a Decade
Christin Melton
TOP - Daily
in
Conference Correspondent
NCCN Updates Guidelines on Breast Cancer Treatment
Christin Melton
TOP - Daily
in
Breast Cancer
Incyte Will Seek Approval of Ruxolitinib in Myelofibrosis Based on Positive Phase III Data
Christin Melton
TOP - Daily
in
Cancer Center Profile
Novel SRC Inhibitor Might Help Overcome Trastuzumab Resistance in Breast Cancer
Christin Melton
TOP - Daily
in
Breast Cancer
Fish Oil May Prevent Muscle Loss in Cancer Patients Undergoing Chemotherapy
Christin Melton
TOP - Daily
Ovarian Cancer Treatment for Medicare Patients Often Falls Short of Guidelines
Christin Melton
TOP - Daily
Eribulin Improves Overall Survival in Women with Heavily Pretreated Metastatic Breast Cancer
Christin Melton
TOP - Daily
in
Breast Cancer
FDA Sets June Date to Hear Genentech's Arguments for Use of Avastin in Breast Cancer
Christin Melton
TOP - Daily
Intermittent Androgen Suppression Recommended as New Standard in Recurrent Prostate Cancer
Christin Melton
TOP - Daily
in
Genitourinary Cancers
Balloon Kyphoplasty Associated with Less Pain and Greater Mobility
Christin Melton
TOP - Daily
Crizotinib New Drug Application Fast-Tracked by the FDA
Christin Melton
TOP - Daily
FDA Panel Recommends Stricter Process for Accelerated Approval of Cancer Drugs
Christin Melton
TOP - Daily
FDA Approves Mobile MIM Radiology Application for Portable Devices
Christin Melton
TOP - Daily
Last modified: February 7, 2011
Home
Issues
2022
May 2022 - Vol 15 No 3
March 2022 - Vol 15 No 2
January 2022 - Vol 15 No 1 – Online Only
2021
November 2021 - Vol 14 No 7
October 2021 - Vol 14 No 6 | Biosimilars
September 2021 - Vol 14 No 5
July 2021 - Vol 14 No 4
May 2021 - Vol 14 No 3
March 2021 - Vol 14 No 2
January 2021 - Vol 14 No 1
2020
November 2020, Vol 13, No 6
September 2020 - Vol 13 no 5
July 2020 - Vol 13 no 4
May 2020 - Vol 13 no 3
March 2020 - Vol 13 no 2
January 2020 - Vol 13 No 1
2019
November 2019 - Vol 12 No 4
August 2019 - Vol 12 No 3
May 2019 - Vol 12 No 2
February 2019 - Vol 12 No 1
Issue Archive
Special Issues
Supplements
ASK THE EXPERT: First-Line Treatment of Metastatic Non-small cell Lung Cancer
Part 1
Guide to New FDA Approvals
2019 Fourth Annual Guide
2018 Third Annual Guide
2017 Second Annual Guide
2016 First Annual Guide
Categories
Conference Correspondent
ASCO 2021 Wrap-Up - Breast Cancer
Web Exclusives
Ovarian Cancer Overview
Interview with the Innovators
All Web Exclusives
Drug Updates
FDA Approvals, News & Updates
In the News
Press Releases
Online First
Media Library
Videos
Audiocasts
Quick Quiz
CE
About
About TOP
Advertise
Editorial Board
Contact Us
Resources
Submit
Author Guidelines
Sign Up Now!
To sign up for our newsletter or print publications, please enter your contact information below and click "Subscribe".
First Name
*
Last Name
*
Email Address
*
Email Address (Verify)
*
TOP
Print Edition
We will request your mailing address on the next page.
TOP
E-Newsletters and Communications
JHOP
Print Edition
We will request your mailing address on the next page.
JHOP
E-Newsletters and Communications
I have reviewed and consent to the terms of
TOP
's
Privacy Policy
, and
TOP
has my permission to retain my information in its database, and to forward pertinent communications to me.